Q326 IDEX Corporation Earnings Call - IDEX CORP

Financial Performance:

• Q3 2026 organic revenue grew 8% (exceeding the 5-7% guidance range), with total orders reaching nearly $1 billion (up 13% organically).
• Adjusted EBITDA margin expanded 50 bps YoY to 27.8% (above the 27.0-27.5% range), and adjusted EPS grew 15% to $2.33 (above the $2.20-2.25 range).
• Year-to-date organic sales are up 6%, adjusted EBITDA margin is up 50 bps, and adjusted EPS is up 14%.
• Free cash flow totaled $214 million, representing a 124% conversion rate.
• Liquidity ended the quarter at over $1.2 billion with gross leverage improved to 1.8x (down from 2.1x).
• Gross margins expanded 70 bps to 45.2%, driven by volume leverage and productivity.

Guidance and Future Outlook:

• Full-year 2026 guidance raised: Organic growth outlook increased to 6.5-6.8% (from 5-6%); adjusted EBITDA margin tightened to 27.1-27.3% (from 26.8-27.3%); adjusted EPS midpoint raised by $0.16 to $8.91-$8.96 (from $8.70-$8.85).
• Expect Q4 margins to decline sequentially due to reduced production days and planned maintenance shutdowns.
• Full-year 2026 capital expenditure (CapEx) expected at ~$110 million with free cash flow conversion of at least 100%.
• Share repurchase plan maintained at ~$75 million per quarter for the remainder of 2026, with flexibility for M&A and portfolio decisions.
• Management anticipates sustained double-digit earnings growth, targeting high 30s to 40% incremental margins net of reinvestment.

Business Segments and Product Lines:

• HST Segment: Organic sales up 13%; organic orders up 21% to a record $468 million. Growth driven by data centers, semiconductor consumables, and space/defense. Life sciences business remained flat year-to-date, offsetting base analytical instrument growth.
• FMT Segment: Organic sales up 4%; organic orders up 11% to a record $349 million. Growth led by semiconductor and municipal water applications; sequential improvement noted in energy and agriculture, despite declines in chemical valves.
• FSDP Segment: Organic sales up 6%; organic orders up 1%. Bandit clamping products drove growth via aerospace demand, while dispensing returned to growth.
• Intelligent Water Platform: The Paraspec cloud-based analytics platform continues to grow in the high single digits, integrating flow monitoring, robotic inspection, and AI-enabled software for municipalities.
• New Product/Tech: Mott expanded into semiconductor purification and space filtration; Muon shifted electroforming expertise to data center optical circuits; Miwan re-engineered laser etching for space RF antennas.

Market and Competitive Landscape:

• Advantage Markets: Data centers, semiconductor, space/defense, and water remain primary growth engines, now representing over one-third of the portfolio.
• AI & Data Centers: Demand remains healthy with large, unpredictable order tranches; supply chain constraints are monitored but not currently disrupted.
• Industrial Broadening: Signs of recovery emerging in agriculture (preseason ordering) and energy (terminal automation), though chemicals remains fatigued due to input cost pressures.
• Competitive Moat: Proprietary "tunability" allows lateral application of component technologies across verticals, expanding Total Addressable Market (TAM) and accelerating time-to-market without bureaucratic overhead.

Risks and Challenges:

• Inflation: Stubborn input costs and elevated energy prices persist; managed via value-based pricing (approx. 2% pricing impact on top line) and productivity gains.
• Macro Uncertainty: Chemicals sector remains challenged; broader industrial demand remains mixed but stabilizing.
• Market Volatility: Data center orders are lumpy and unpredictable, creating short-term variability in revenue recognition.
• Valuation: M&A deal pricing remains robust, potentially delaying large-scale acquisitions despite an active pipeline of proprietary conversations.

Management Commentary and Tone:

• Tone: Highly confident and positive; management described results as a "validation of our strategic thesis" and highlighted "compounding effects" of execution.
• Strategy: Emphasis on the "80-20" playbook to allocate resources to high-growth areas; strong belief in the durability of advantage markets.
• Innovation: Highlighted speed and agility in adapting technologies (e.g., applying medical respiratory tech to data center optics) as a key differentiator.

Analyst Questions and Answers:

• Growth Indicators: Management identified small, sequential step-ups in order rates across distributors as early signals of industrial broadening; agriculture and energy showing specific signs of bottoming.
• HST Visibility: Data center orders are lumpy; however, backlog is sufficient to support growth. Management expects HST to sustain high single-digit growth rates into 2027.
• M&A Pipeline: Activity level remains high with proprietary conversations ongoing; discipline maintained due to current valuation levels, though focus remains on "bolt-on" capabilities for platform extension.
• Incremental Margins: Confirmed that incremental margins remain in the high 30s to 40% range, inclusive of necessary growth investments for the next cycle.
• Pricing: Pricing power is estimated at ~2% of top line, sufficient to cover inflation and maintain margins; expected to continue exceeding cost increases.

Other Key Points:

• Culture: Management credited a flat organizational structure and entrepreneurial autonomy for the ability to rapidly pivot resources and identify cross-business opportunities.
• Acquisition Success: Recent acquisitions (Mott, Muon, Miwan) are exceeding expectations, contributing significantly to margin expansion and growth in non-core areas.
• Life Sciences: While facing a legacy platform roll-off, the sector is expected to return to growth as innovation cycles and institutional demand normalize.
• ESG: Mention of environmental and macroeconomic factors as standard monitoring points, but no specific near-term negative impacts identified.